New drug AMT-253 enters human trials for Hard-to-Treat cancers
NCT ID NCT06209580
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 28 times
Summary
This study tests a new drug called AMT-253 in people with advanced melanoma or other solid tumors that have spread or cannot be removed. The goal is to find a safe dose and see if the drug can shrink tumors. About 96 participants will join this early-phase trial.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.